TROP2-XPAT

**TROP2-XPAT** is an investigational **protease-activated T-cell engager prodrug** from **Amunix** designed for the treatment of **solid tumors** that express **trophoblast cell surface antigen 2**. It is built on the company's **XPAT** platform, which uses XTEN-based masking to keep the molecule relatively inactive systemically and then enables activation by proteases enriched in the tumor microenvironment. The intended mechanism is selective engagement of **T cells** against **TROP2-expressing tumor cells** while reducing **on-target, off-tumor toxicity** that has historically limited T-cell engagers in solid tumors. Based on the provided context, the program was reported in **early development** and approaching **lead selection** as of 2020, with no identified brand name or clinical-stage formulation disclosed.

Other names

TROP2 XPATTROP-2 XPATTROP 2 XPATTROP2-targeted XPATTROP-2-targeted XPATTROP 2-targeted XPATprotease-activated T cell engager prodrug targeting TROP2